Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01903993 · BASELINE

Baseline characteristics

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" · Source last updated 2019-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      143
    2. group Id
      BG001
      value
      144
    3. group Id
      BG002
      value
      287
    units
    Participants
groups
  1. description
    Participants received docetaxel 75 milligram per squared meters (mg/m\^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
    id
    BG000
    title
    Docetaxel
  2. description
    Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
    id
    BG001
    title
    Atezolizumab
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.4
          value
          61.8
        2. group Id
          BG001
          spread
          9.2
          value
          61.5
        3. group Id
          BG002
          spread
          9.3
          value
          61.6
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          67
        2. group Id
          BG001
          value
          51
        3. group Id
          BG002
          value
          118
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          76
        2. group Id
          BG001
          value
          93
        3. group Id
          BG002
          value
          169
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Intent to treat (ITT) population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. In the efficacy analyses, the ITT population, participants were grouped according to the treatment arm to which they were assigned.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      143
    2. group Id
      BG001
      value
      144
    3. group Id
      BG002
      value
      287
    units
    Participants
groups
  1. description
    Participants received docetaxel 75 milligram per squared meters (mg/m\^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
    id
    BG000
    title
    Docetaxel
  2. description
    Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
    id
    BG001
    title
    Atezolizumab
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.4
          value
          61.8
        2. group Id
          BG001
          spread
          9.2
          value
          61.5
        3. group Id
          BG002
          spread
          9.3
          value
          61.6
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          67
        2. group Id
          BG001
          value
          51
        3. group Id
          BG002
          value
          118
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          76
        2. group Id
          BG001
          value
          93
        3. group Id
          BG002
          value
          169
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Intent to treat (ITT) population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. In the efficacy analyses, the ITT population, participants were grouped according to the treatment arm to which they were assigned.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice